<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010525</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-016-ST-001</org_study_id>
    <nct_id>NCT05010525</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors</brief_title>
  <acronym>REACH</acronym>
  <official_title>A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Antengene Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antengene Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is A Phase Ib/II Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy&#xD;
      of ATG 016 Monotherapy in Patients with Advanced Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety,&#xD;
      Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients with Advanced&#xD;
      Solid Tumors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD in Phase I</measure>
    <time_frame>16 months</time_frame>
    <description>MTD will be evaluated using the NCI-CTCAE, Version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D in Phase I</measure>
    <time_frame>16 months</time_frame>
    <description>RP2D will be determined under the guidance of the SRC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs</measure>
    <time_frame>25 months</time_frame>
    <description>Toxicity will be graded according to the NCI CTCAE, Version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAEs</measure>
    <time_frame>25 months</time_frame>
    <description>Toxicity will be graded according to the NCI CTCAE, Version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR in Phase II</measure>
    <time_frame>25 months</time_frame>
    <description>Based on 2006 IWG Response Criteria, evaluated by IRC: ORR (CR + PR + mCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) in Phase I/II</measure>
    <time_frame>16 months</time_frame>
    <description>DCR (CR + PR + mCR + HI + SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) in Phase I/II</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS）</measure>
    <time_frame>12 months</time_frame>
    <description>The estimates of Kaplan-Meier</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ATG-016-20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG-016-35mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG-016-50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG-016-65mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>65 mg QD×5/ week as the initial dose in the Dose Escalation Phase, with a treatment cycle of 21 days,1-5/week will be the initial dose of this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-016</intervention_name>
    <description>48 patients enrolled, orally, each 3 week (21-day) a cycle</description>
    <arm_group_label>ATG-016-20mg</arm_group_label>
    <arm_group_label>ATG-016-35mg</arm_group_label>
    <arm_group_label>ATG-016-50mg</arm_group_label>
    <arm_group_label>ATG-016-65mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understand and voluntarily sign informed Consent (ICF) prior to any&#xD;
             assessment/procedure related to study.&#xD;
&#xD;
          2. Age ≥18 years at ICF signature.&#xD;
&#xD;
          3. Estimated life expectancy of minimum of 12 weeks.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at ICF signature.&#xD;
&#xD;
          5. Subjects must have at least one measurable lesion as defined by RECIST version 1.1.&#xD;
&#xD;
          6. Females of childbearing potential must agree to use effective contraception from the&#xD;
             time ICF signature until 180 days after the last dose. Females of childbearing&#xD;
             potential include those who are premenopausal and those who are 2 years&#xD;
             postmenopausal. Blood pregnancy tests must be negative for female of childbearing&#xD;
             potential must have a negative serum pregnancy test at Screening.&#xD;
&#xD;
        Inclusion Criteria Only for Phase Ib study (Dose Escalation and Expansion phase)&#xD;
&#xD;
        1. Histological or cytological confirmation of a solid tumor, and have progressed despite&#xD;
        standard therapy(ies), or are intolerant to standard therapy(ies), or have no standard&#xD;
        therapy(ies) exists.&#xD;
&#xD;
        Inclusion Criteria Only for Phase II&#xD;
&#xD;
          1. Penile squamous cell carcinomas confirmed by cytology or histology cannot be excised&#xD;
             by radical surgery, or postoperative recurrence or metastasis which is not suitable&#xD;
             for platinum chemotherapy or platinum resistance or platinum failure.&#xD;
&#xD;
          2. Nasopharyngeal carcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with any of the following conditions will not be enrolled in this study.&#xD;
&#xD;
          1. Central nervous system (CNS) metastases and involvement.&#xD;
&#xD;
          2. A history of bone marrow or organ transplantation.&#xD;
&#xD;
          3. Prior ATG-016 administration or other XPO1 inhibitor treatment.&#xD;
&#xD;
          4. Known to be allergic to the active or inactive ingredients of ATG-016 or drugs with&#xD;
             similar chemical structure, or the subject is hypersensitive.&#xD;
&#xD;
          5. Prior therapy with any investigational drugs or systemic anticancer treatment (eg, a&#xD;
             period of 5 'half-lives' of drugs, whichever is longer) within 28 days at the time of&#xD;
             ICF signature.&#xD;
&#xD;
          6. Received extensive radiation within 28 days at the time of ICF signature or expect to&#xD;
             undergo radical radiotherapy during the study period.&#xD;
&#xD;
          7. Received major surgery within 28 days at the time of ICF signature or expect to&#xD;
             proceed a major surgical treatment during the study period.&#xD;
&#xD;
          8. Any toxicities unresolved to Grade 1 or baseline from prior anti-tumor therapy&#xD;
             (According to NCI-CTCAE 5.0) with the exception of alopecia, within 28 days at the&#xD;
             time of ICF signature.&#xD;
&#xD;
          9. Any uncontrolled active infection requiring parenteral treatment of antibiotics,&#xD;
             antivirals, or antifungals at the time of ICF signature or within one week of Cycle 1&#xD;
             Day 1 (C1D1). Active hepatitis B virus (HBV) infection (Hepatitis B surface antigen&#xD;
             [HBsAg] positive) or active HCV infection (HCV-RNA positive at screening).&#xD;
&#xD;
         10. A history of HIV infection and/or acquired immunodeficiency syndrome.&#xD;
&#xD;
         11. Received immunosuppressive medication within 14 days at the time of ICF signature.&#xD;
&#xD;
         12. Cardiovascular diseases of clinical significance&#xD;
&#xD;
         13. Inadequate bone marrow reserve or organ function as demonstrated by any of the&#xD;
             following laboratory values:&#xD;
&#xD;
         14. Have a history of another primary malignancy within 5 years prior to starting study&#xD;
             treatment, with following exceptions: malignancy tumors treated by radical therapy and&#xD;
             have not been recurred, such as carcinoma in situ of the cervix, basal cell carcinoma&#xD;
             or squamous cell carcinoma of the skin, papillary thyroid carcinoma, etc.&#xD;
&#xD;
         15. Inability or unwillingness to comply with the requirement for oral drug&#xD;
             administration, or presence of a gastrointestinal diseases or other clinical&#xD;
             conditions that would compromise the absorption of study drug, eg, refractory nausea&#xD;
             and vomiting, inability to swallow the formulated product, or previous significant&#xD;
             bowel resection, etc.&#xD;
&#xD;
         16. Active or a history of bleeding within 6 months.&#xD;
&#xD;
         17. Received any live attenuated vaccination within 28 days at the signature of ICF.&#xD;
&#xD;
         18. Judgment by the investigator that the subject should not participate in the study by&#xD;
             consideration of the complications or other conditions which might affect their&#xD;
             adherence to the protocol.&#xD;
&#xD;
         19. Female subjects who are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongsheng Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guoxue lane, Chengdu, Sichuan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimin Sun</last_name>
    <phone>13701803117</phone>
    <email>jasmine.sun@antengene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaobei He</last_name>
    <phone>13916910751</phone>
    <email>xiaobei.he@antengene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chonqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weiqi Nian, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Weiqi Nian, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiaomen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qin Lin, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Qin Lin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

